Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Vertex Pharmaceuticals's Debt-to-EBITDA or its related term are showing as below:
MEX:VRTX'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.18 Med: 0.42 Max: 11.14
Current: 0.38
During the past 13 years, the highest Debt-to-EBITDA Ratio of Vertex Pharmaceuticals was 11.14. The lowest was 0.18. And the median was 0.42.
MEX:VRTX's Debt-to-EBITDA is ranked better than 68.04% of 291
companies
in the Biotechnology industry
Industry Median: 1.14
vs MEX:VRTX: 0.38
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Vertex Pharmaceuticals Debt-to-EBITDA Related Terms
Vertex Pharmaceuticals Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Vertex Pharmaceuticals's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:VRTX vs REGN, ALNY, RVMD: Debt-to-EBITDA Comparison
For the Biotechnology subindustry, Vertex Pharmaceuticals's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vertex Pharmaceuticals Debt-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Vertex Pharmaceuticals's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Vertex Pharmaceuticals's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Vertex Pharmaceuticals (MEX:VRTX) has a Debt-to-EBITDA of 0.42 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Vertex Pharmaceuticals. This is near median its historical median of 0.42. Over the past decade, Vertex Pharmaceuticals' Debt-to-EBITDA has ranged from 0.18 to 11.14. According to the industry distribution chart, Vertex Pharmaceuticals ranks #93 out of 291 companies in the Biotechnology industry, placing it in the top 32%.
Is Vertex Pharmaceuticals' Debt-to-EBITDA too high?
Vertex Pharmaceuticals' current Debt-to-EBITDA of 0.42 is near median its 10-year median of 0.42. Over the past 10 years, this metric has ranged from a low of 0.18 to a high of 11.14. The Biotechnology industry median Debt-to-EBITDA is 1.14. Vertex Pharmaceuticals' value of 0.42 is 63.2% below this industry median. Based on the distribution chart, Vertex Pharmaceuticals ranks #93 out of 291 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Vertex Pharmaceuticals has a GF Score™ of 91/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Vertex Pharmaceuticals' Debt-to-EBITDA compare to REGN and ALNY?
According to the Biotechnology industry distribution chart, Vertex Pharmaceuticals ranks #93 out of 291 companies for Debt-to-EBITDA. This puts Vertex Pharmaceuticals in the upper half of its industry. The industry median Debt-to-EBITDA is 1.14. Vertex Pharmaceuticals' value of 0.42 is 63.2% below this benchmark. Historically, Vertex Pharmaceuticals' own Debt-to-EBITDA has ranged from 0.18 to 11.14 over the past decade. While the company's 10-year median is 0.42 vs. the industry median of 1.14, Vertex Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Biotechnology company?
The median Debt-to-EBITDA among Biotechnology companies is 1.14, based on 291 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vertex Pharmaceuticals's current Debt-to-EBITDA of 0.42 is 63.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Vertex Pharmaceuticals. For the Biotechnology industry, the median Debt-to-EBITDA is 1.14 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vertex Pharmaceuticals's current Debt-to-EBITDA is 0.42, which is near median its own 10-year median of 0.42. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vertex Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Vertex Pharmaceuticals (MEX:VRTX) is currently considered Fairly Valued. The stock's GF Value™ is MXN8,809.34, compared to a current price of MXN8,319.00 — trading 5.6% below its estimated fair value. The current Debt-to-EBITDA is 0.42, which is near median its 10-year median of 0.42 and 63.2% below the Biotechnology industry median of 1.14. Vertex Pharmaceuticals' overall GF Score™ is 91/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Vertex Pharmaceuticals (MEX:VRTX), the current Debt-to-EBITDA is 0.42 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vertex Pharmaceuticals (MEX:VRTX) Overvalued in 2026?
Based on GuruFocus' analysis, Vertex Pharmaceuticals stock appears to be undervalued.
The current stock price of MXN8,319.00 is trading 5.6% below its estimated GF Value™ of MXN8,809.34.
GuruFocus considers Vertex Pharmaceuticals to be Fairly Valued.
Key valuation signals for MEX:VRTX:
Debt-to-EBITDA: 0.42 (near median its 10-year median of 0.42)
GF Value™: MXN8,809.34 vs. price of MXN8,319.00 (5.6% below fair value)
Industry Position: 63.2% below the Biotechnology median (#93 of 291)
No single metric tells the full story. See the MEX:VRTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
91GF Score
Get the complete analysis for MEX:VRTX
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:VRTX has been successfully added to your 
